(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 17.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Ionis Pharmaceuticals's revenue in 2025 is $705,138,000.On average, 9 Wall Street analysts forecast IONS's revenue for 2025 to be $101,350,851,754, with the lowest IONS revenue forecast at $93,671,581,549, and the highest IONS revenue forecast at $110,814,342,561. On average, 10 Wall Street analysts forecast IONS's revenue for 2026 to be $134,766,359,582, with the lowest IONS revenue forecast at $116,839,107,420, and the highest IONS revenue forecast at $150,491,949,652.
In 2027, IONS is forecast to generate $180,468,254,638 in revenue, with the lowest revenue forecast at $64,221,767,888 and the highest revenue forecast at $220,659,000,013.